Photo of David J. Kuter,  MD, DPhil

David J. Kuter, MD, DPhil

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-4000
Fax: (617) 724-6801


kuter.david@mgh.harvard.edu

David J. Kuter, MD, DPhil

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Professor, Medicine, Harvard Medical School
  • Director, Clinical Hematology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

My basic science research involves hematopoiesis. We investigate the mechanism of apoptosis in megakaryocytes and platelets. We also assess the molecular mechanism by which thrombopoietin is regulated and interacts with its receptor, c-Mpl. My clinical research is focussed on thrombosis/hemostasis and hematopoietic growth factors. We are studying the use of thrombopoietin in ITP, the use of Novel Erythropoiesis-Stimulating Protein (NESP) in anemic chemotherapy patients and the role of thrombopoietin in preventing chemotherapy-induced thrombocytopenia. We are studying the thrombophilia of malignancy and the role of low-molecular weight heparins in its treatment and in the prevention of catheter-related thrombosis.

Publications

Powered by Harvard Catalyst
  • Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Huntingt) 2015; 29:282-94. PubMed
  • Kuter DJ, Macahilig C, Grotzinger KM, Poston SA, Wang PF, Dawson KL, Ward M. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Int J Hematol 2015; 101:255-63. PubMed
  • Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood 2014. PubMed
  • Makar RS, Zhukov OS, Sahud MA, Kuter DJ. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. Am J Hematol 2013; 88:1041-4. PubMed
  • Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M. Myeloid growth factors. J Natl Compr Canc Netw 2013; 11:1266-90. PubMed
  • Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, Jun S. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. British Journal of Haematology 2013; 161:411-23. PubMed
  • Schulman S, Awad MM, Kuter DJ. Neutrophil-erythrocyte rosettes in autoimmune hemolytic anemia. Am J Hematol 2012. PubMed
  • Kuter DJ. Romiplostim. Cancer Treat Res 2010; 157:267-88. PubMed
  • Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363:1889-99. PubMed
  • Lennerz JK, Kuter DJ, Hasserjian R, Iafrate J. Massive hepatomegaly and involvement by Janus kinase 2-positive myeloproliferative neoplasm. Hepatology 2010; 52:1855-6. PubMed
  • Davids MS, Murali MR, Kuter DJ. Serum free light chain analysis. Am J Hematol 2010; 85:787-90. PubMed
  • Rabin DU, Kuter DJ, Liebman HA, Bussel JB. What do healthcare providers ask their patients with immune thrombocytopenia? Am J Hematol 2010; 85:629-31. PubMed
  • Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin Hematol 2010; 47:243-8. PubMed
  • Bussel JB, Kuter DJ. New thrombopoietic agents: introduction. Semin Hematol 2010; 47:211. PubMed
  • Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168-86. PubMed
  • Kuter DJ, Gernsheimer TB. Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol Oncol Clin North Am 2009; 23:1193-211. PubMed
  • Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009; 114:3748-56. PubMed
  • Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009; 27:3518-25. PubMed
  • Bussel JB,Kuter DJ,Pullarkat V,Lyons RM,Guo M,Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2008; 113:2161-71. PubMed
  • Davis AK,Makar RS,Stowell CP,Kuter DJ,Dzik WH. ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13. Transfusion 2009; 49:206-13. PubMed
  • Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 2009; 60:193-206. PubMed
  • Kuter DJ. Thrombopoietin and Thrombopoietin Mimetics in the Treatment of Thrombocytopenia. Annu Rev Public Health 2008. PubMed
  • Kuter DJ. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Eur J Haematol Suppl 2008. PubMed
  • Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. British Journal of Haematology 2007; 139:351-62. PubMed
  • Park JH, Spitzer T, Kuter DJ. Successful treatment of pure red cell aplasia with autologous stem cell transplantation. Am J Hematol 2007; 82:812-4. PubMed
  • Moore A, Lau E, Yang C, Mackool B, Kuter DJ. Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma. Am J Clin Oncol 2007; 30:329-31. PubMed
  • Abel GA, Hays JT, Decker PA, Croghan GA, Kuter DJ, Rigotti NA. Effects of biochemically confirmed smoking cessation on white blood cell count. Mayo Clin Proc 2005; 80:1022-8. PubMed
  • Kuter DJ. The promise of thrombopoietins in the treatment of ITP. Clin Adv Hematol Oncol 2005; 3:464-6. PubMed
  • Rosovsky RP, Kuter DJ. Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management. Hematol Oncol Clin North Am 2005; 19:183-202, vii. PubMed
  • Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2002; 21:46-53. PubMed
  • Taghian AG, Assaad SI, Niemierko A, Kuter I, Younger J, Schoenthaler R, Roche M, Powell SN. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 2001; 93:1806-11. PubMed
  • Fleischmann KH, Kuter DJ, Coley CM, Rathmell JP. Practice guidelines often fail to keep pace with the rapid evolution of medicine: a call for clinicians to remain vigilant and revisit their own practice patterns. Reg Anesth Pain Med 2010; 35:4-7. PubMed
  • Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol 1999; 106:345-56. PubMed
Hide